You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis
  1. Young Ho Lee
  1. Correspondence to Professor Young Ho Lee, Division of Rheumatology, Korea University Medical Center, Seoul, Republic of Korea; lyhcgh{at}korea.ac.kr

https://doi.org/10.1136/annrheumdis-2017-212452

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    I read with great interest the article by Reginster and colleagues1 regarding the effectiveness of chondroitin sulfate (CS) in the treatment of symptomatic knee osteoarthritis (OA). This randomised, double-blind trial demonstrated that pharmaceutical-grade CS is superior to placebo and equivalent to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee OA, indicating that this formulation of CS should be considered a first-line treatment in the …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles